Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) Subsidiary's Product Eribulin Mesylate Injection Receives U.S. FDA Approval
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that its subsidiary, Nanjing King-Friend Pharmaceutical Co., Ltd., recently received ANDA approval from the U.S. Food and Drug Administration ("U.S. FDA") for Eribulin Mesylate Injection (1mg/2mL). The drug is indicated for patients with metastatic breast cancer who have previously received at least two chemotherapy regimens, and for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen. The newly approved product further enriches the company's international product pipeline and strengthens its international market presence.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that its subsidiary, Nanjing King-Friend Pharmaceutical Co., Ltd., recently received an ANDA approval notice from the U.S. Food and Drug Administration ("U.S. FDA") for Eribulin Mesylate Injection (1mg/2mL). The drug is indicated for patients with metastatic breast cancer who have previously received at least two chemotherapy regimens, and for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen. The newly approved product further enriches the company's international product pipeline and strengthens the company's international market presence.
Related Articles
LX TECHNOLOGY (02436) repurchased 5,400 shares on October 20 for HK$109,000.
HING YIP HLDGS (00132) subsidiary enters into finance lease with Zhenlai County Rongxiang Heating
SIHUAN PHARM (00460): The injectable polycaprolactone microsphere facial filler and injectable sodium hyaluronate composite solution independently developed by Meiyan Space have been approved for marketing in Hong Kong.
LX TECHNOLOGY (02436) repurchased 5,400 shares on October 20 for HK$109,000.
HING YIP HLDGS (00132) subsidiary enters into finance lease with Zhenlai County Rongxiang Heating
SIHUAN PHARM (00460): The injectable polycaprolactone microsphere facial filler and injectable sodium hyaluronate composite solution independently developed by Meiyan Space have been approved for marketing in Hong Kong.
